Document published by the source itself
Robust detection of SARS-CoV-2 variants at the point-of-care
How variant mutations are tracked for diagnostic impact, using a point-of-care system as the case.
Source
This white paper describes how relevant mutations are identified and assessed for diagnostic impact in real-time through an ongoing pandemic, with a focus on the successful coverage of SARS-CoV-2 variants by the point-of-care Thermo Fisher Scientific™ Accula™ SARS-CoV-2 Test.
This entry describes what the document covers; the document itself is the authority. Listing it is not agreement with its conclusions.
Key takeaways
How variant mutations are tracked for diagnostic impact, using a point-of-care system as the case.
Review and references
Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.
2026-10-09
2026-10-09
professional use
Interested in these solutions?
Submit a sourcing request with the assays, volumes, and timeline of your own project.